{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:50:40Z","timestamp":1788184240504,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.neulet.2026.138667","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:46:09Z","timestamp":1782229569000},"page":"138667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Jak1 inhibition reduces acute allodynia induced by specific upstream cytokines in rats: implications for the onset of Jak1 pain modulation"],"prefix":"10.1016","volume":"883","author":[{"given":"Steve","family":"McGaraughty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Strasburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Ciura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal Naseri","family":"Kouzehgarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Wilper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"Bertels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Housley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2026.138667_b0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neulet.2026.138667_b0010","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"21","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.neulet.2026.138667_b0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semcdb.2008.08.010","article-title":"Inteferons pen the JAK-STAT pathway","volume":"19","author":"Schindler","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.neulet.2026.138667_b0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neulet.2026.138667_b0025","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1523\/JNEUROSCI.3055-19.2020","article-title":"Type I interferons act directly on nociceptors to produce pain sensitization: Implications for viral infection-induced pain","volume":"40","author":"Barrag\u00e1n-Iglesias","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2026.138667_b0030","doi-asserted-by":"crossref","first-page":"15427","DOI":"10.1074\/jbc.RA120.013815","article-title":"The palmitoyl acyltransferases ZDHHC5 and ZDHHC8 are uniquely present in DRG axons and control retrograde signaling via the Gp130\/JAK\/STAT3 pathway","volume":"295","author":"Collura","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2026.138667_b0035","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/j.pain.0000000000000158","article-title":"Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK\/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model","volume":"156","author":"Fang","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.neulet.2026.138667_b0040","doi-asserted-by":"crossref","first-page":"9845","DOI":"10.1523\/JNEUROSCI.5161-13.2014","article-title":"Deletion of interleukin-6 signal transducer gp130 in small sensory neurons attenuates mechanonociception and down-regulates TRPA1 expression","volume":"34","author":"Malsch","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2026.138667_b0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj8186","article-title":"Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors","volume":"14","author":"Tavares-Ferreira","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neulet.2026.138667_b0050","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/ecco-jcc\/jjab099","article-title":"Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis","volume":"15","author":"Ghosh","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.neulet.2026.138667_b0055","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","article-title":"A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition","volume":"61","author":"McInnes","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.neulet.2026.138667_b0060","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.3390\/jcm13237185","article-title":"Real-life use of Filgotinib in rheumatoid arthritis: a retrospective cohort study","volume":"13","author":"Raimondo","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neulet.2026.138667_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/1744666X.2022.2049242","article-title":"Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis","volume":"18","author":"Strand","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.neulet.2026.138667_b0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13075-019-2059-8","article-title":"Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.neulet.2026.138667_b0075","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/rheumatology\/keaa770","article-title":"Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.neulet.2026.138667_b0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000535285","article-title":"Abrocitinib provides rapid and sustained improvement in skin pain and is associated with improved quality of life outcomes in adult and adolescent patients with moderate-to-severe atopic dermatitis","volume":"240","author":"Thyssen","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.neulet.2026.138667_b0085","doi-asserted-by":"crossref","first-page":"34356","DOI":"10.1038\/srep34356","article-title":"Interferon alpha inhibits spinal cord synaptic and nociceptive transmission via neuronal-glial interactions","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neulet.2026.138667_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783725","article-title":"Interferons in pain and infections: emerging roles in Neuro-immune and Neuro-glial interactions","volume":"12","author":"Tan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neulet.2026.138667_b0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev.pa.20.040180.002301","article-title":"Efficient analysis of experimental observations","volume":"20","author":"Dixon","year":"1980","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neulet.2026.138667_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588543","article-title":"The JAK1 selective inhibitor ABT 317 blocks Signaling through interferon-\u03b3 and common \u03b3 chain cytokine receptors to reverse autoimmune diabetes in NOD mice","volume":"11","author":"Ge","year":"2020","journal-title":"Front. in Immunol."},{"key":"10.1016\/j.neulet.2026.138667_b0105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/14397595.2018.1484269","article-title":"ABBV-105, a selective and irreversible inhibitor of Bruton\u2019s tyrosine kinase, is efficacious in multiple preclinical models of inflammation","volume":"29","author":"Goess","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.neulet.2026.138667_b0110","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1016\/j.autrev.2024.103736","article-title":"Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: a scoping review","volume":"24","author":"Challoumas","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neulet.2026.138667_b0115","first-page":"1","article-title":"Selective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016-2023)","volume":"25","author":"Gao","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neulet.2026.138667_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/bjd\/ljae404","article-title":"Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level up)","volume":"192","author":"Silverberg","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.neulet.2026.138667_b0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ard.2025.01.005","article-title":"Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model Ann","volume":"84","author":"Simon","year":"2025","journal-title":"Rheum. Dis."},{"key":"10.1016\/j.neulet.2026.138667_b0130","doi-asserted-by":"crossref","unstructured":"G. Ishikawa, C. Kwon, Y. Fujii, Comparison of the effects of peficitinib and tofacitinib in the adjuvant-induced arthritis rat model. Eur. J. Pharmacol. 15 (2023) 941:175490. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175490.","DOI":"10.1016\/j.ejphar.2023.175490"},{"key":"10.1016\/j.neulet.2026.138667_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13075-024-03354-1","article-title":"Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6\/JAK\/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons","volume":"15","author":"Makabe","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.neulet.2026.138667_b0140","doi-asserted-by":"crossref","first-page":"11943","DOI":"10.3390\/ijms252211943","article-title":"Direct effects of the Janus kinase inhibitor Baricitinib on sensory neurons","volume":"25","author":"Vazquez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neulet.2026.138667_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002671","article-title":"JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation","volume":"9","author":"Nyirenda","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.neulet.2026.138667_b0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cei\/uxac085","article-title":"Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response","volume":"210","author":"Valli","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.neulet.2026.138667_b0155","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920917249","article-title":"Interferon-\u03b3 facilitates the synaptic transmission between primary afferent C-fibres and lamina I neurons in the rat spinal dorsal horn via microglia activation","volume":"16","author":"Reischer","year":"2020","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neulet.2026.138667_b0160","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916644927","article-title":"Interferon-gamma potentiates NMDA receptor signaling in spinal dorsal horn neurons via microglia-neuron interaction","volume":"12","author":"Sonekatsu","year":"2016","journal-title":"Mol. Pain"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394026001679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394026001679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:25:53Z","timestamp":1786033553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394026001679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S0304394026001679"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2026.138667","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Jak1 inhibition reduces acute allodynia induced by specific upstream cytokines in rats: implications for the onset of Jak1 pain modulation","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2026.138667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"138667"}}